Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials
Max Kates(Duke Medical Center), Trinity J. Bivalacqua(University of Pennsylvania), Joshua J. Meeks(Northwestern University), Nina Mikkilineni(Columbia University Irving Medical Center), Robert S. Svatek(The University of Texas at San Antonio Health Science Center), Charles G. Drake(Columbia University Irving Medical Center), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Woonyoung Choi(Johns Hopkins University), Sima P. Porten(City College of San Francisco), Colin P. Dinney(The University of Texas MD Anderson Cancer Center), Peter C. Black(University of British Columbia), David J. McConkey(Johns Hopkins University), Alexander S. Baras(Johns Hopkins University), Kara A. Lombardo(Johns Hopkins University), Andrés Matoso(Johns Hopkins University), Aaron Brant(Johns Hopkins University), Chris Anderson(UNSW Sydney), Seth P. Lerner(Baylor College of Medicine), Marcus J. Daniels(Johns Hopkins University)
Cited by 167
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress
|New England Journal of Medicine|2005|3.1k